[go: up one dir, main page]

WO2001070757A3 - Thiocetals et thioethers permettant d'inhiber l'expression de la molecule-1 d'adhesion cellulaire vasculaire (vcam-1) - Google Patents

Thiocetals et thioethers permettant d'inhiber l'expression de la molecule-1 d'adhesion cellulaire vasculaire (vcam-1) Download PDF

Info

Publication number
WO2001070757A3
WO2001070757A3 PCT/US2001/009049 US0109049W WO0170757A3 WO 2001070757 A3 WO2001070757 A3 WO 2001070757A3 US 0109049 W US0109049 W US 0109049W WO 0170757 A3 WO0170757 A3 WO 0170757A3
Authority
WO
WIPO (PCT)
Prior art keywords
vcam
thioketals
thioethers
expression
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/009049
Other languages
English (en)
Other versions
WO2001070757A2 (fr
Inventor
Charles Q Meng
Lee K Hoong
Patricia K Somers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atherogenics Inc
Original Assignee
Atherogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atherogenics Inc filed Critical Atherogenics Inc
Priority to EP01920617A priority Critical patent/EP1289944A2/fr
Priority to JP2001568958A priority patent/JP2003528109A/ja
Priority to AU4765101A priority patent/AU4765101A/xx
Priority to AU2001247651A priority patent/AU2001247651B2/en
Priority to CA002403823A priority patent/CA2403823A1/fr
Publication of WO2001070757A2 publication Critical patent/WO2001070757A2/fr
Publication of WO2001070757A3 publication Critical patent/WO2001070757A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)

Abstract

L'invention concerne des thiocétals et des thioéthers permettant d'inhiber l'expression de la molécule-1 d'adhésion cellulaire vasculaire (VCAM-1), et pouvant être utilisés pour traiter les maladies induites par la VCAM-1, y compris les troubles inflammatoires, les maladies cardio-vasculaires, les maladies oculaires, les maladies auto-immunes, les troubles neurologiques, et le cancer. En outre, ces composés peuvent être utilisés pour traiter l'hyperlipidémie et/ou l'hypercholestérolémie.
PCT/US2001/009049 2000-03-21 2001-03-21 Thiocetals et thioethers permettant d'inhiber l'expression de la molecule-1 d'adhesion cellulaire vasculaire (vcam-1) Ceased WO2001070757A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01920617A EP1289944A2 (fr) 2000-03-21 2001-03-21 Thiocetals et thioethers permettant d'inhiber l'expression de la molecule-1 d'adhesion cellulaire vasculaire (vcam-1)
JP2001568958A JP2003528109A (ja) 2000-03-21 2001-03-21 Ｖｃａｍ−１の発現を阻害するためのチオケタール及びチオエーテル
AU4765101A AU4765101A (en) 2000-03-21 2001-03-21 Thioketals and thioethers for inhibiting the expression of vcam-1
AU2001247651A AU2001247651B2 (en) 2000-03-21 2001-03-21 Thioketals and thioethers for inhibiting the expression of vcam-1
CA002403823A CA2403823A1 (fr) 2000-03-21 2001-03-21 Thiocetals et thioethers permettant d'inhiber l'expression de la molecule-1 d'adhesion cellulaire vasculaire (vcam-1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19104600P 2000-03-21 2000-03-21
US60/191,046 2000-03-21

Publications (2)

Publication Number Publication Date
WO2001070757A2 WO2001070757A2 (fr) 2001-09-27
WO2001070757A3 true WO2001070757A3 (fr) 2002-03-14

Family

ID=22703910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009049 Ceased WO2001070757A2 (fr) 2000-03-21 2001-03-21 Thiocetals et thioethers permettant d'inhiber l'expression de la molecule-1 d'adhesion cellulaire vasculaire (vcam-1)

Country Status (5)

Country Link
EP (1) EP1289944A2 (fr)
JP (1) JP2003528109A (fr)
AU (2) AU2001247651B2 (fr)
CA (1) CA2403823A1 (fr)
WO (1) WO2001070757A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087645B2 (en) 1997-05-14 2006-08-08 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US7189870B2 (en) 1997-05-14 2007-03-13 Atherogenic, Inc. Compounds and methods for the inhibition of the expression of VCAM-1
US8252840B2 (en) 2007-03-26 2012-08-28 Salutria Pharmaceuticals Llc Methods of derivatives of probucol for the treatment of type II diabetes

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1446113A4 (fr) * 2001-10-25 2006-12-06 Atherogenics Inc Composes et methodes de traitement d'un rejet de greffe
ITMI20020597A1 (it) 2002-03-22 2003-09-22 Nicox Sa Derivati del probucolo
WO2004007423A1 (fr) 2002-07-12 2004-01-22 Atherogenics, Inc. Nouvelles formes de sels d'ethers et d'esters de probucol faiblement solubles
JP4550800B2 (ja) 2003-01-13 2010-09-22 アセロジエニクス・インコーポレイテツド プロブコールおよびその誘導体のエステルおよびエーテルの製造方法
WO2005102323A2 (fr) 2004-04-20 2005-11-03 Atherogenics, Inc. Procede de preparation d'esters et d'ethers de probucol et de ses derives
JP2008505097A (ja) * 2004-07-01 2008-02-21 アセロジエニクス・インコーポレイテツド 糖尿病性血管疾患を治療するための化合物および方法
EP1844009A4 (fr) * 2004-12-17 2010-04-21 Roland O Stocker Préparations et méthodes pour le traitement de troubles cardio-vasculaires
US7897776B2 (en) 2007-04-23 2011-03-01 Salutria Pharmaceuticals Llc Sulfonamide containing compounds for treatment of inflammatory disorders
NZ708314A (en) * 2009-03-18 2017-08-25 Resverlogix Corp Quinazolinones for use as anticancer agents
EP2961828A4 (fr) 2013-02-28 2016-08-03 Harvard College Procédés et compositions pour mobiliser des cellules souches
US10947311B2 (en) 2015-11-20 2021-03-16 The Board Of Trustees Of The Leland Stanford Junior University VCAM-1 mediated methods and compositions for treating aging-associated impairments
CN110452877A (zh) * 2018-05-07 2019-11-15 北京吉尚立德生物科技有限公司 一种肺癌实体瘤原代细胞的培养方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418648A1 (fr) * 1989-09-08 1991-03-27 Hoechst Aktiengesellschaft 4-Hydroxy-tétra-hydro-pyranne-2-ones, ainsi que les dérivés de dihydroxyacides correspondants, des sels et des esters, procédé pour leur préparation, des préparations pharmaceutiques ainsi que des précurseurs
US5512595A (en) * 1993-04-20 1996-04-30 Adir Et Compagnie Substituted phenoxyisobutyric acids and esters
WO1998051289A2 (fr) * 1997-05-14 1998-11-19 Atherogenics, Inc. Monoesters de probucol destines au traitement de troubles cardio-vasculaires et inflammatoires
WO2000028332A1 (fr) * 1998-11-09 2000-05-18 Atherogenics, Inc. Methodes et compositions abaissant les niveaux de cholesterol dans le plasma

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418648A1 (fr) * 1989-09-08 1991-03-27 Hoechst Aktiengesellschaft 4-Hydroxy-tétra-hydro-pyranne-2-ones, ainsi que les dérivés de dihydroxyacides correspondants, des sels et des esters, procédé pour leur préparation, des préparations pharmaceutiques ainsi que des précurseurs
US5512595A (en) * 1993-04-20 1996-04-30 Adir Et Compagnie Substituted phenoxyisobutyric acids and esters
WO1998051289A2 (fr) * 1997-05-14 1998-11-19 Atherogenics, Inc. Monoesters de probucol destines au traitement de troubles cardio-vasculaires et inflammatoires
WO1998051662A2 (fr) * 1997-05-14 1998-11-19 Atherogenics, Inc. Composes et methodes d'inhibition de l'expression de vcam-1
WO2000028332A1 (fr) * 1998-11-09 2000-05-18 Atherogenics, Inc. Methodes et compositions abaissant les niveaux de cholesterol dans le plasma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DE MEGLIO, P. ET AL: "New derivatives of clofibrate and probucol. Preliminary studies on hypolipemic activity", FARMACO, ED. SCI. (1985), 40(11), 833-44, XP001015770 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087645B2 (en) 1997-05-14 2006-08-08 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US7189870B2 (en) 1997-05-14 2007-03-13 Atherogenic, Inc. Compounds and methods for the inhibition of the expression of VCAM-1
US8252840B2 (en) 2007-03-26 2012-08-28 Salutria Pharmaceuticals Llc Methods of derivatives of probucol for the treatment of type II diabetes

Also Published As

Publication number Publication date
WO2001070757A2 (fr) 2001-09-27
AU4765101A (en) 2001-10-03
EP1289944A2 (fr) 2003-03-12
JP2003528109A (ja) 2003-09-24
AU2001247651B2 (en) 2007-01-04
CA2403823A1 (fr) 2001-09-27

Similar Documents

Publication Publication Date Title
PL343904A1 (en) Compounds and methods for the inhibition of the expression of vcam-1
WO2001070757A3 (fr) Thiocetals et thioethers permettant d'inhiber l'expression de la molecule-1 d'adhesion cellulaire vasculaire (vcam-1)
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
FR15C0070I2 (fr) Composes heteroaromatiques azotes pour le traitement des maladies de cancer
EP1352897A3 (fr) Dérivés d'adamantane pour le traitement de maladies inflammatiores, immunes et cardiovasculaires
WO2004052280A3 (fr) Composes anti-angiogenique et utilisations de ceux-ci dans le traitement du cancer
PT1641764E (pt) Inibidores de p38 quinase a base de heterociclo de 5 elementos
AU2002352706A1 (en) N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
WO2004064716A3 (fr) Psoriasis et acide eicosapentaenoique
WO2006134494A3 (fr) Composes anti-connexine et leurs utilisations
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP1251126A3 (fr) Derives de benzenesulfonyle a substitution fluor pour le traitment d'inflammation
WO2002009683A3 (fr) Therapie anti-aldosterones destinee a prevenir ou traiter les troubles lies a une inflammation
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
AU2002363411A1 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
WO2004032864A3 (fr) Composes x-nitro, leurs compositions pharmaceutiques et leurs utilisations
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
AU2001247471A1 (en) Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
AU2003270540A1 (en) Treatment of cyclooxygenase-3 mediated diseases and disorders
WO2000054770A8 (fr) Compositions pharmaceutiques renfermant des sous-unites de troponine, ou des fragments ou des homologues desdites sous-unites, et leur utilisation pour inhiber l'angiogenese
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2002214950A1 (en) Determination of the ability of patients to respond to tumour treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2403823

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 568958

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001247651

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001920617

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001920617

Country of ref document: EP